All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Salarius Pauses Phase 1/2 Trial Investigating Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Following Death

October 19th 2022

Salarius Pharmaceuticals has voluntarily paused enrollment of new patients into a phase 1/2 trial investigating seclidemstat in patients with Ewing sarcoma, sarcomas with FET-family translocations, and myxoid liposarcoma due to the death of a patient.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma

October 19th 2022

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

Novel Treatments Begin to Rival Transplant in AML and DLBCL

October 18th 2022

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

Ubamatamab Monotherapy Elicits Responses in Heavily Pretreated Ovarian Cancer

October 18th 2022

Ubamatamab monotherapy produced early clinical activity and an acceptable risk/benefit profile in heavily pretreated patients with ovarian cancer.

Sylvester Researcher Aims for Early Detection of Ovarian Cancer with Support from $500,000 Philanthropic Gift

October 18th 2022

Sophia George, PhD, is hoping to find new strategies for early detection of ovarian cancer, a disease that is particularly deadly for African American, Caribbean, and Jewish women.

European Commission Approves Second-line Axi-cel for DLBCL/HGBL

October 18th 2022

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

October 18th 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

October 18th 2022

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

FDA Grants Orphan Drug Designation to PCLX-001 for AML

October 17th 2022

The FDA has granted an orphan drug designation to PCLX-001 for the treatment of patients with acute myeloid leukemia.

FDA Grants Orphan Drug Designation to ET140203 for Hepatoblastoma

October 17th 2022

The FDA has granted an orphan drug designation to ET140203 for the treatment of patients with hepatoblastoma.

Uproleselan Plus Chemotherapy Could Provide MRD Benefit in Relapsed/Refractory AML

October 17th 2022

Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.

Pembrolizumab Confers Long-Term OS Benefit in Head and Neck Squamous Cell Carcinoma

October 17th 2022

Pembrolizumab, alone and in combination with chemotherapy, maintained an overall survival benefit compared with cetuximab plus chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma at 4 years.

Novel ADC and CAR T Approaches Broaden the DLBCL Treatment Landscape

October 17th 2022

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

Researchers Find Tumor Microbiome Interactions May Identify New Approaches for Pancreatic Cancer Treatment

October 17th 2022

Investigators from Rutgers Cancer Institute of New Jersey examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival.

Durvalumab Plus Standard-of-Care Chemotherapy Shakes Up First-line Care in Advanced Biliary Tract Cancers

October 17th 2022

Do-Youn Oh, MD, PhD, highlights the nuances of the TOPAZ-1 trial data that signal new pathways forward for investigative efforts in advanced biliary tract cancers.

Pembrolizumab Delivers Promising Results in Advanced Clear Cell Gynecologic Cancer

October 17th 2022

Pembrolizumab monotherapy induced durable clinical outcomes in heavily pretreated patients with clear cell gynecologic cancer.

Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma

October 16th 2022

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

Proteosome Inhibitors Plus CD38 Antibodies Elicit Encouraging Responses in Multiple Myeloma

October 15th 2022

Peter Voorhees, MD, discusses key points from his presentation on proteasome inhibitors in multiple myeloma and positive data with the agents in the transplant-eligible and transplant-ineligible populations.